| Literature DB >> 36006274 |
Hashim A Mahdi1,2,3, Fadi S Qashqari4, Sumyya H Hariri4, Shahad Bamerdah5, Shahad A Altayyar5, Hazim M Almalki5, Fayez A Alwadani5, Renan A Alabbasi5, Mohammed H Alqahtani6, Mohammad Alfelali7, Ramon Z Shaban8,9,10,11, Robert Booy2,3,11, Harunor Rashid2,3,11.
Abstract
This study estimates the point prevalence of symptomatic respiratory tract infections (RTIs) among returned Hajj pilgrims and their contacts in 2021. Using the computer-assisted telephone interview (CATI) technique, domestic pilgrims were invited to participate in this cross-sectional survey two weeks after their home return from Hajj. Of 600 pilgrims approached, 79.3% agreed to participate and completed the survey. Syndromic definitions were used to clinically diagnose possible influenza-like illnesses (ILI) and COVID-19. Median with range was applied to summarise the continuous data, and frequencies and proportions were used to present the categorical variables. Simple logistic regression was carried out to assess the correlations of potential factors with the prevalence of RTIs. The majority of pilgrims (88.7%) reported receiving at least two doses of the COVID-19 vaccine before Hajj. Eleven (2.3%) pilgrims reported respiratory symptoms with the estimated prevalence of possible ILI being 0.2%, and of possible COVID-19 being 0.4%. Among those who were symptomatic, five (45.5%) reported that one or more of their close contacts had developed similar RTI symptoms after the pilgrims' home return. The prevalence of RTIs among pilgrims who returned home after attending the Hajj 2021 was lower compared with those reported in the pre-pandemic studies; however, the risk of spread of infection among contacts following Hajj is still a concern.Entities:
Keywords: COVID-19; Hajj; influenza-like illnesses; pilgrims; respiratory tract infections
Year: 2022 PMID: 36006274 PMCID: PMC9413585 DOI: 10.3390/tropicalmed7080182
Source DB: PubMed Journal: Trop Med Infect Dis ISSN: 2414-6366
Participants’ socio-demographic characteristics (n = 476).
| Characteristics | n (%) |
|---|---|
| Age (years) | |
| 18–25 | 35 (7.4) |
| 26–39 | 118 (24.8) |
| 40–55 | 203 (42.7) |
| 56–64 | 111 (23.4) |
| ≥65 | 8 (1.7) |
| Gender | |
| Male:Female | 257:219 (54:46) |
| Nationality | |
| Saudi Arabia | 337 (70.8) |
| Egypt | 29 (6.1) |
| Pakistan | 27 (5.7) |
| India | 21 (4.4) |
| Algeria | 10 (2.1) |
| Others | 52 (10.9) |
| Education | |
| No education | 32 (6.7) |
| Primary/elementary school certificate | 51 (10.7) |
| High school certificate | 83 (17.4) |
| Diploma | 33 (6.9) |
| Bachelor’s degree | 206 (43.3) |
| Higher university degree | 71 (14.9) |
Participants’ medical history and vaccination status (n = 476).
| Variable | n (%) |
|---|---|
| Presence of pre-existing comorbidities | |
| Diabetes | 67 (14.1) |
| Hypertension | 62 (13) |
| Chronic lung diseases | 11 (2.3) |
| Chronic heart diseases | 6 (1.3) |
| Obesity | 4 (0.8) |
| Others | 6 (1.3) |
| Smoking status | |
| Non-smoker | 359 (81.2) |
| Current smoker | 46 (10.4) |
| Past smoker | 29 (6.6) |
| Passive smoker | 8 (1.8) |
| Influenza vaccine | |
| No | 244 (51.3) |
| Yes | 232 (48.7) |
| COVID-19 vaccine, dose 1 | |
| No | 7 (1.5) |
| Yes | 469 (98.5) |
| COVID-19 vaccine, dose 2 | |
| No | 54 (11.3) |
| Yes | 422 (88.7) |
Reported symptoms of respiratory tract infections among participants (n = 11).
|
|
|
| Rhinitis | 9 (81.8) |
| Fatigue | 9 (81.8) |
| Cough | 6 (54.5) |
| Sore throat | 5 (45.5) |
| Subjective fever | 4 (36.4) |
| Headache | 4 (36.4) |
| Smell/taste dysfunction | 2 (18.2) |
| Short of breath (dyspnoea) | 2 (18.2) |
| Myalgia | 2 (18.2) |
| Vomiting | 1 (9.1) |
|
|
|
| Subjective fever, and cough | 1 (9.1) |
| Subjective fever, cough, sore throat, rhinitis, dyspnoea, smell/taste dysfunction, myalgia, fatigue, headache, and vomiting | 1 (9.1) |
| Subjective fever, cough, dyspnoea, smell/taste dysfunction, myalgia, and fatigue | 1 (9.1) |
| Subjective fever, cough, rhinitis, and fatigue | 1 (9.1) |
| Cough, rhinitis, fatigue, and headache | 2 (18.2) |
| Sore throat, rhinitis, and fatigue | 2 (18.2) |
| Sore throat, rhinitis, and headache | 1 (9.1) |
| Sore throat, rhinitis, fatigue, and headache | 1 (9.1) |
| Rhinitis and fatigue | 1 (9.1) |
Associations of potential factors with respiratory tract infections among participants (n = 11).
| Variable | n (%) | OR (95% CI) | |
|---|---|---|---|
| Age (years) | |||
| 18–25 | 2 (5.7) | Reference | 0.3 |
| 26–39 | 5 (4.2) | 0.7 (0.01–3.9) | |
| 40–55 | 2 (1) | 0.2 (0.02–1.2) | |
| 56–64 | 2 (1.8) | 0.3 (0.04–2.2) | |
| ≥65 | 0 (0) | 0.0 (0.0–0.0) | |
| Gender | |||
| Male | 9 (1.9) | Reference | 0.3 |
| Female | 6 (2.7) | 1.4 (0.4–4.7) | |
| Education | |||
| No education | 1 (3.1) | 1.1 (0.1–9) | 0.4 |
| Primary/elementary school certificate | 0 (0) | 0.0 (0.0–0.0) | |
| High school certificate | 1 (1.2) | 0.4 (0.1–3.3) | |
| Diploma | 1 (3) | 1.0 (0.1–8.7) | |
| University degree or higher | 8 (2.9) | Reference | |
| Pre-existing medical conditions | |||
| No | 7 (2) | Reference | 0.4 |
| Yes | 4 (3.3) | 1.7 (0.5–5.9) | |
| Smoking status | |||
| Non-smoker | 9 (2.3) | Reference | 0.4 |
| Current smoker | 2 (4.3) | 1.9 (0.4–9.3) | |
| Influenza vaccine | |||
| No | 3 (1.2) | Reference | 0.1 |
| Yes | 8 (3.4) | 2.8 (0.7–10.9) | |
| COVID-19 vaccine | |||
| No | 1 (1.9) | Reference | 0.8 |
| Yes | 10 (2.4) | 1.3 (0.2–10.2) |